1 / 56

Optimal Strategies for DVT Prophylaxis: Translating Evidence into Practice

DVT-WRAP SlideCAST. Optimal Strategies for DVT Prophylaxis: Translating Evidence into Practice. Samuel Z. Goldhaber, MD Cardiovascular Division Brigham and Women’s Hospital Professor of Medicine Harvard Medical School. The Challenge. DVT/ PE are rampant but often preventable.

nia
Télécharger la présentation

Optimal Strategies for DVT Prophylaxis: Translating Evidence into Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DVT-WRAP SlideCAST Optimal Strategies for DVT Prophylaxis: Translating Evidence into Practice Samuel Z. Goldhaber, MD Cardiovascular Division Brigham and Women’s Hospital Professor of Medicine Harvard Medical School

  2. The Challenge DVT/ PE are rampant but often preventable. • Hospitalized patients are at risk, but prophylactic measures are often omitted. • Behavior Modification and Quality Improvement strategies: - Electronic, Human alerts - 3-screen alert with default prophylaxis - Continuum of Care (ensure prophylaxis from admission to discharge, to SNF, and at home)

  3. Lung with PE

  4. PE SXS/ Signs (PIOPED II) • Dyspnea (79%) • Tachypnea (57%) • Pleuritic pain (47%) • Leg edema, erythema, tenderness, palpable cord (47%) • Cough/ hemoptysis (43%) Stein PD. Am J Med 2007; 120: 871-879

  5. Incidence 900,000 PEs/ DVTs in USA in 2002. Estimated 296,000 PE deaths: 7% treated, 34% sudden and fatal, and 59% undetected. Heit J. ASH Abstract 2005 ----------------------------------------- 762,000 PEs/ DVTs in EU in 2004. Thromb Haemostas 2007; 98: 756

  6. The high death rate from PE (exceeding acute MI!) and the high frequency of undiagnosed PE causing “sudden cardiac death” emphasize the need for improved preventive efforts. Failure to institute prophylaxis is a much bigger problem with Medical Service patients than Surgical Service patients.

  7. Annual # At-Risk for VTE: US Hospitals • 7.7 million Medical Service inpatients • 3.4 million Surgical Service inpatients • Based upon ACCP guidelines for VTE prophylaxis Anderson FA Jr, et al. Am J Hematol 2007; 82: 777-782

  8. Malignant Gliomas (N=9,489) and VTE • California Cancer Registry • 2-year VTE Incidence: 7.5% • 16 VTE events per 100 person-years during 1st 6 months • Risk factors: older age, neurosurgery • VTE: 30% increased risk of death J Neurosurg 2007; 106: 601-608

  9. Outpatient and Inpatient VTE are Linked • 74% of VTEs present in outpatients. • 42% of outpatient VTE patients have had recent surgery or hospitalization. • Only 40% had received VTE prophylaxis. Spencer FA, et al. Arch Intern Med 2007; 167: 1471-1475

  10. 25 20 15 10 5 0 ICOPER Cumulative Mortality 17.5% Mortality (%) 7 14 30 60 90 Days From Diagnosis Lancet 1999; 353: 1386-1389

  11. Progression of Chronic Venous Insufficiency From UpToDate 2006

  12. Risk Factors Linking Venous and Arterial TE: Biologically Plausible • Activation of platelets and coagulation proteins • Increased fibrin turnover • Inflammation • Lipid profiles

  13. Dabish 20-Year Cohort: VTE, Subsequent CV Events • Assessed risk of MI, Stroke • 25,199 with DVT • 16,925 with PE • 163,566 population controls Sorensen HT. Lancet 2007; 370: 1773-1779

  14. RR CV Event in PE Patients Sorensen HT. Lancet 2007; 370: 1773-1779

  15. Cardiovascular Risk Factors and VTE (N=63,552 meta-analysis) RFRR Obesity 2.3 Hypertension 1.5 Diabetes 1.4 Cigarettes 1.2 High Cholesterol 1.2 Ageno W. Circulation 2008; 117: 93-102

  16. Risk Factors Meta-Analysis Implications • RFs for atherothrombosis are also associated with VTE • Cardiovascular RFs may be involved in pathogenesis of VTE • Atherosclerosis and VTE are not completely distinct entities. Ageno W. Circulation 2008; 117: 93-102

  17. Obesity and VTE: NHDS Stein PD. Am J Med 2005; 118: 978-980

  18. Eat Veggies and Lower VTE Risk; Careful with Red Meat Steffen LM. Circulation2007;115:188-195

  19. Reversible Risk Factors • Nutrition: eat fruits, veggies, fish; less red meat • Quit cigarettes • Lose weight/ exercise • Prevent DM/ metabolic syndrome • Control hypertension • Lower cholesterol

  20. VTE Prophylaxis in 19,958 Medical Patients/9 Studies (Meta-Analysis) • 62% reduction in fatal PE • 57% reduction in fatal or nonfatal PE • 53% reduction in DVT Dentali F, et al. Ann Intern Med 2007; 146: 278-288

  21. Intermittent Pneumatic CompressionMeta-Analysis in Postop Patients • 2,270 patients in 15 randomized trials • IPC devices reduced DVT risk by 60% (Relative Risk 0.40, 95% CI 0.29-0.56, p< 0.001) Urbankova J. ThrombHaemost 2005; 94: 1181-5

  22. The Amin Report: Prophylaxis Rates in the US • Studied 196,104 Medical Service discharges from 227 hospitals (Premier® database). • VTE prophylaxis rate was 62%. • ACCP-deemed appropriate prophylaxis rate was 34%. J ThrombHaemostas 2007; 5: 1610-6

  23. Medical Patient Prophylaxis in Canada • Studied 1,894 Medical Service discharges from 29 hospitals. • VTE prophylaxis was indicated in 90% of patients. • ACCP-deemed appropriate prophylaxis rate was 16%. Thrombosis Research 2007; 119: 145-155

  24. ENDORSE : WORLDWIDE (Lancet 2008; 371: 387-394) 68,183 patients; 32 countries; 358 sites First patient enrolled August 2, 2006;Last patient enrolled January 4, 2007

  25. 40% receive ACCPRec. Px Worldwide Prophylaxis Status for 68,183 Patients 52% at Risk for VTE (50% receive ACCPrecommended prophy) Surgical Medical 64% at Risk for VTE 42% at Risk for VTE 59% receive ACCPRec. Px

  26. We have initiated trials to change MD behavior and improve implementation of VTE prophylaxis—not trials of specific types of prophylaxis—eAlert RCT, eAlert cohort, human Alert, 3-screen eAlert.

  27. Quality Improvement Initiative to Improve Clinical Practice Randomized controlled trial to issue or withhold electronic alerts to MDs whose high-risk patients were not receiving DVT prophylaxis. Kucher N, et al. NEJM 2005;352:969-977

  28. Definition of “High Risk” VTE risk score ≥ 4 points: • Cancer 3 (ICD codes) • Prior VTE 3 (ICD codes) • Hypercoagulability 3 (Leiden, ACLA) • Major surgery 2 (> 60 minutes) • Bed rest 1 (“bed rest” order) • Advanced age 1 (> 70 years) • Obesity 1 (BMI > 29 kg/m2) • HRT/OC 1 (order entry)

  29. VTE risk score > 4 No prophylaxis N = 2,506 Randomization CONTROL No computer alert N = 1,251 INTERVENTION: Single alert N = 1,255 Kucher N, et al. NEJM 2005;352:969-977

  30. DVT Alert Screen

  31. Rule Logic – Alert Details

  32. Option A

  33. Option B

  34. Option C or “Done”

  35. 90-Day Primary Endpoint Intervent.ControlHazard Ratiop N=1255 N=1251 (95% CI) Total VTE 61 (4.9) 103 (8.2) 0.59 (0.43-0.81) 0.001 Acute PE 14 (1.1) 35 (2.8) 0.40 (0.21-0.74) 0.004 Proximal DVT 10 (0.8) 23 (1.8) 0.47 (0.20-1.09) 0.08 Distal DVT 5 (0.4) 12 (1.0) 0.42 (0.15-1.18) 0.10 UE DVT 32 (2.5) 33 (2.6) 0.97 (0.60-1.58) 0.90 Kucher N, et al. NEJM 2005;352:969-977

  36. 100 98 Intervention 96 %Freedom from DVT/PE 94 Control 92 90 0 30 60 90 Time (days) Primary End Point Number at risk Intervention 1255 977 900 853 Control 1251 976 893 839 Kucher N, et al. NEJM 2005;352:969-977

  37. Electronic Alert Cohort Purpose: • To evaluate use of the VTE risk score and eAlert system in “real world” setting • To validate the efficacy of continued use of the eAlert after discontinuing randomization • To determine whether VTE prophylaxis prescribing changed following NEJM publication J Thromb Thrombolysis 2008;25: 146-50

  38. Electronic Alert Cohort • We identified 866 consecutive patients between January 2004 and July 2006 following completion of original study • All patients met same inclusion/ exclusion NEJM eAlert criteria • “Rules” for generating alerts remained identical to original VTE eAlert study Baroletti S et al. J Thrombosis Thrombolysis 2008; 25: 146-50)

  39. Cohort Study: Results P <0.001

  40. Cohort Study: Results Baroletti S et al. J Thrombosis Thrombolysis 2008; 25: 146-50

  41. Cohort Summary (N=866) • 18% high risk patients were not prophylaxed in the NEJM eAlert RCT • After “turning off” randomization, 9% high risk patients were not prophylaxed in the cohort study • 82% were Medical Service patients • Symptomatic VTE at 90 days occurred in 5.1% (Baroletti S et al. J Thrombosis Thrombolysis 2008; 25: 146-50)

  42. VTE Prophylaxis: hALERT • We initiated a multicentered RCT of human alerts (hALERT) (N=2,500) • Objective: to recruit hospitals that differ from BWH re: IT, community vs. academic, urban vs. suburban/rural, location within USA. • Can a human alert be more effective than an electronic alert?

More Related